Daily Intake of Multivitamin & Mineral Supplementation Effects on Biological Age of Relatively Healthy Middle-aged Individuals (CEDIRA)

October 29, 2024 updated by: Andrea Maier, National University of Singapore

Centrum; the Effect of Daily Intake of Multivitamin & Mineral Supplementation, on Biological Age in Relatively Healthy Middle-aged Individuals (CEDIRA)

Micronutrients, such as vitamins and minerals, are required to sustain fundamental physiological processes in individuals. As individuals age, the risk of having suboptimal levels of micronutrients increases due to several age-related changes affecting their digestion and assimilation processes. Suboptimal levels of micronutrients have been associated with increased risk of chronic diseases and accelerated ageing. Three years intake of a multivitamin and mineral supplement (MVM) improved global cognition, episodic memory and executive function in older adults. Furthermore, suboptimal micronutrient levels have been associated with a higher biological age, and diet and lifestyle interventions might lower the biological age measured by methylation clocks. Therefore, further evaluation is warranted to determine if MVM supplementation could improve the biological age and clinical outcomes in individuals with a higher biological age.

Study Overview

Detailed Description

Accelerated ageing, characterized by a reduced function of multiple organ systems, can be measured by biological, clinical and digital biomarkers of aging. These biomarkers of aging are used to express the biological age of individuals. A higher biological age is not only associated with suboptimal micronutrients levels, but can also be reduced through lifestyle intervention, dietary intervention and nutrient supplementation. A frequently used biological biomarker of ageing is DNA methylation (DNAm) status, which is measured using a set of algorithm known as DNAm clock. This value has been accepted as a good indicator to capture fundamental molecular processes tied to the ageing process. Several studies using Vitamin D, Vitamin B12, and Vitamin C and E have shown positively modify DNAm clock, thus biological age. Henceforth, this study aims to determine if MVM supplementation can reduce the biological age in participants who are biologically older as assessed by DNAm clock.

Rationale for Study Population Middle aged individuals with a high biological age have a high risk of age-releated disesases. Efforts are being made to prevent the development and incidence of age-related diseases and therewith to reduce healthcare costs. Relatively healthy (no chronic disease), middle-aged (40-60 (inclusive) years old) individuals with a biological age higher than their chronological age will be included in this randomized, double-blinded, placebo-controlled trial.

Rationale for Study Design CEDIRA is a randomized, double-blinded, placebo-controlled trial including relatively healthy middle-aged individuals with a higher biological age to evaluate the effect of MVM supplementation for 12 months on biological age and other clinical and biological characteristics such as micronutrient levels in blood, anthropometrics, glucose control, lipid profile, cognition, muscle strength, skin health, lifestyle behaviour, and quality of life.

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Singapore, Singapore, 117597
        • Recruiting
        • Healthy Longevity Translational Research Programme, Level 3, MD 11, 10 Medical Dr, Yong Loo Lin School of Medicine, National University of Singapore
        • Contact:
        • Contact:
        • Contact:
          • Andrea Britta Maier, MD PhD FRACP
      • Singapore, Singapore, 159964
        • Recruiting
        • Center for Healthy Longevity, Clinic L, Alexandra Hospital, 378 Alexandra Road
        • Contact:
        • Contact:
          • Andrea Britta Maier, MD PhD FRACP
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria

Participants will be recruited if they fall in the following categories:

  1. Relatively healthy middle aged (40-60 years) man or woman;
  2. Completed the pre-screening requirements and has managed to schedule the screening visit;
  3. Met the randomization criteria after the screening visit i.e., your biological age (as measured by blood DNA methylation) is greater than the chronological age;
  4. Able to attend all 4 research visits for screening and research data collection at the NUHS Centre for Healthy Longevity (CHL) at Alexandra Hospital or MD11, National University of Singapore.
  5. Willing to wear an OURA ring for 14 consecutive days after each study visits.
  6. Willing to download study platform application into their mobile phone throughout the study period.

Exclusion Criteria

Participants will NOT be recruited if they fall in any one or more of the following categories:

  1. BMI lower than 18 kg/m2 or higher than or equal to 30 kg/m2 [25];
  2. Pre-existing, or history of major cardiovascular diseases (coronary artery disease, heart failure, stroke, peripheral vascular disease, pulmonary hypertension), severe/uncontrolled hypertension (more than 1 prescribed medication), rheumatic heart disease, congenital heart disease, deep vein thrombosis, pulmonary embolism;
  3. Type 1 diabetes and Type 2 diabetes;
  4. Active cancer or treatment of cancer in the last 3 years;
  5. Chronic obstructive pulmonary disease (COPD), severe asthma (taking daily medications);
  6. Pregnant women or women planning pregnancy in the next 12 months;
  7. Multiple sclerosis or autoimmune/immune deficiency diseases such as Rheumatic arthritis, HIV, Crohn's disease;
  8. Recent history of sepsis or infection (within 3 months of in-patient hospitalisation);
  9. Any psychiatric disease or neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Lewy body dementia, and any eating disorders;
  10. Hepatitis and liver cirrhosis (independent of severity);
  11. Severe kidney disease (GFR less than 30 ml/min/1.73 m2);
  12. Skin disease (on systemic medication);
  13. Individuals who are on another trial that requires them taking similar or partially similar investigational product (Appendix 1);
  14. Individuals who are advised by their medical practitioner to take a MVM supplement;
  15. Refuse to stop taking any non-prescribed supplements that contain the investigational product (Appendix 1) within one month before the screening visit and during the study period;
  16. Taking a medically prescribed supplements that contains 2 or more of the ingredients of the investigational product (Appendix 1);
  17. Individuals with planned hospitalization in the next 12 months;
  18. Any serious medical illness which in the PI's judgment may jeopardise the participant by his or her participation in this study or may hamper his or her ability to perform and complete procedures required in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Multivitamin/Mineral Supplement (MVM)
Participants in this arm will take 1.2g/day of MVM supplement from CENTRUM for 12 months.
Each participant will be given 180 MVM tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally daily, in the morning before food. Participants will be asked to return the remainder of dispensed MVM tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm.
Placebo Comparator: Placebo
Participants in this arm will take 1.2g/day of placebo for 12 months.
Each participant will be given 180 placebo tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally, daily, in the morning before food. Participants will be asked to return the remainder of dispensed placebo tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm. The placebo pills and bottles will be identical in appearance as MVM to ensure effective blinding.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in blood DNA methylation status, years
Time Frame: Baseline, 6 months and 12 months
DNA methylation aging clock
Baseline, 6 months and 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Mass Index (BMI) change
Time Frame: Baseline, 6 months and 12 months
comparison of BMI at baseline, interim and end of trial
Baseline, 6 months and 12 months
Waist-to-hip ratio change
Time Frame: Baseline, 6 months and 12 months
comparison of waist-to-hip ratio at baseline, interim and end of trial
Baseline, 6 months and 12 months
Body fat mass (kg) change
Time Frame: Baseline, 6 months and 12 months
comparison of body fat mass at baseline, interim and end of trial
Baseline, 6 months and 12 months
Skeletal muscle mass (kg) change
Time Frame: Baseline, 6 months and 12 months
comparison of skeletal muscle mass at baseline, interim and end of trial
Baseline, 6 months and 12 months
Percentage body fat (%) change
Time Frame: Baseline, 6 months and 12 months
comparison of percentage body fat at baseline, interim and end of trial
Baseline, 6 months and 12 months
Systolic blood pressure (mm Hg) change
Time Frame: Baseline, 6 months and 12 months
comparison of systolic blood pressure at baseline, interim and end of trial
Baseline, 6 months and 12 months
Diastolic blood pressure (mm Hg) change
Time Frame: Baseline, 6 months and 12 months
comparison of diastolic blood pressure at baseline, interim and end of trial
Baseline, 6 months and 12 months
Pulse rate (BPM) change
Time Frame: Baseline, 6 months and 12 months
comparison of pulse rate at baseline, interim and end of trial
Baseline, 6 months and 12 months
Skin elasticity (mm/time) change
Time Frame: Baseline, 6 months and 12 months
comparison of skin elasticity measured by he resistance of the skin to the negative pressure (firmness) and its ability to return into its original position (elasticity) displayed as curves (penetration depth in mm/time) at baseline, interim and end of trial
Baseline, 6 months and 12 months
Skin colour (L* a* b*) change
Time Frame: Baseline, 6 months and 12 months
comparison of skin colour measured using automatic calculation of ITA (Individual Typology Angle) that uses CIE L* a* b* values to classify 6 skin colours from very light to dark at baseline, interim and end of trial
Baseline, 6 months and 12 months
Skin autofluorescence (au) change
Time Frame: Baseline, 6 months and 12 months
comparison of skin autofluorescence levels calculated by dividing the mean value of the emitted light intensity per nm between 420 and 600 nm by the mean value of the excitation light intensity per nm between 300 and 420 nm, expressed in arbitrary units (AU) at baseline, interim and end of trial
Baseline, 6 months and 12 months
Complete blood count
Time Frame: Baseline, 6 months and 12 months
comparison of blood count at baseline, interim and end-of-trial
Baseline, 6 months and 12 months
Change in immune parameters: complete blood count
Time Frame: Baseline, 6 months and 12 months
comparison of immune parameters at baseline, interim and end-of-trial.
Baseline, 6 months and 12 months
Change in immune parameters: inflammatory parameters in serum (mg/dL)
Time Frame: Baseline, 6 months, 12 months
comparison of immune parameters at baseline, interim and end-of-trial
Baseline, 6 months, 12 months
Change in clinical blood parameters: renal function (mg/dL)
Time Frame: Baseline, 6 months and 12 months
comparison of clinical blood parameters at baseline, interim and end-of-trial
Baseline, 6 months and 12 months
Change in clinical blood parameters: lipid profile test (mmol/L)
Time Frame: Baseline, 6 months and 12 months
comparison of clinical blood parameters at baseline, interim and end-of-trial
Baseline, 6 months and 12 months
Change in clinical blood parameters: glucose (mg/dL)
Time Frame: Baseline, 6 months and 12 months
comparison of clinical blood parameters at baseline, 6 months and 12 months
Baseline, 6 months and 12 months
Change in clinical blood parameters: insulin (mg/dL)
Time Frame: Baseline, 6 months and 12 months
comparison of clinical blood parameters at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in clinical blood parameters: glycelated haemoglobin, HbA1C (mmol/mol)
Time Frame: Baseline, 6 months and 12 months
comparison of clinical blood parameters at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in clinical blood parameters: metabolites (mmol/l)
Time Frame: Baseline, 6 months and 12 months
comparison of clinical blood parameters at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in micronutrient levels in blood
Time Frame: Baseline, 6 months and 12 months
comparison of micronutrient levels in blood at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in micronutrient levels in urine
Time Frame: Baseline, 6 months and 12 months
comparison of micronutrient levels in urine at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in cognition (Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Test)
Time Frame: Baseline, 6 months and 12 months
comparison of cognition at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in handgrip strength change (kg)
Time Frame: Baseline, 6 months and 12 months
comparison of handgrip strength at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in quality of life (EuroQoL-5D-5L)
Time Frame: Baseline, 6 months and 12 months
comparison of quality of life at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in sleep quality (modified Pittsburgh Sleep Quality Questionnaire)
Time Frame: Baseline, 6 months and 12 months
comparison of sleep quality at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in sleep quality (Satisfaction, Alertness, Timing, Efficiency and Duration (SATED) Questionnaire)
Time Frame: Baseline, 6 months and 12 months
comparison of sleep quality at baseline, interim and end of trial
Baseline, 6 months and 12 months
Change in dietary intake (3-day Food Record)
Time Frame: Baseline, 6 months and 12 months
comparison of dietary intake at baseline, interim and end of trial
Baseline, 6 months and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Andrea Britta Maier, MD PhD FRACP, National University of Singapore

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 23, 2024

Primary Completion (Estimated)

April 30, 2025

Study Completion (Estimated)

June 30, 2025

Study Registration Dates

First Submitted

October 23, 2024

First Submitted That Met QC Criteria

October 29, 2024

First Posted (Actual)

October 30, 2024

Study Record Updates

Last Update Posted (Actual)

October 30, 2024

Last Update Submitted That Met QC Criteria

October 29, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • CEDIRA-NUS
  • HALEON (Other Grant/Funding Number: HALEON)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe